Europe has rapidly become one of the world’s most dynamic regions for genetic analysis, sequencing technologies, and data-driven precision medicine. From liquid biopsies and transplant monitoring to next-generation bioinformatics platforms, a wave of innovative companies is redefining how genetic data is generated, interpreted, and applied in real clinical settings.

At BiopharmIQ, we track 141 active European companies operating in genetic analysis, sequencing, and enabling technologies. This year, we narrowed that landscape to highlight 10 companies that stand out for their recent funding momentum, clinical trial activity, and technology differentiation.

These companies are shaping the next phase of precision medicine in Europe and represent promising collaboration opportunities for pharmaceutical, diagnostic, and research organizations.

👉🏻 Start with a FREE list of 141 Genetic Analysis Companies in Europe

Hedera Dx (Switzerland)

Focus: Liquid biopsy, NGS-based molecular profiling, precision oncology

Hedera Dx is developing a scalable liquid biopsy platform that enables faster, more accessible tumor profiling for oncology patients. In 2025, the company initiated a major real-world evidence clinical registry to track treatment decisions and outcomes based on molecular profiling results. This dataset positions Hedera Dx as a key player in bridging genomics and clinical care.

Why highlighted:

• New clinical trial/registry launched in 2025

• Series A funding ($17.25M)

• Strong positioning in precision oncology

Devyser (Sweden)

Focus: Genetic testing for transplant medicine, targeted NGS kits

Devyser leads in transplant-focused genetic analysis. Its 2025 multicenter kidney transplant study collects longitudinal genomic and molecular markers to better evaluate graft status, exactly the type of data-rich clinical validation needed in transplant diagnostics.

Why highlighted:

• New clinical trial in 2025 involving transplant genomics

• High-value clinical niche: transplant monitoring

• Strong fit for clinical labs & hospital partnerships

Ophiomics (Portugal)

Focus: AI-driven liver cancer prediction tools, genomics for transplantation

Ophiomics’ HepatoPredict tool combines clinical and molecular signatures to improve patient selection for liver surgery and transplantation. In 2025, the platform progressed through a long-term clinical study, advancing its prognostic value.

Why highlighted:

• Ongoing clinical study using genomic signatures

• Differentiation in liver cancer & transplant genomics

• Clear utility in risk stratification & clinical decisions

SeqOne Genomics (France)

Focus: AI-enabled NGS analysis, genomic workflow automation

SeqOne provides a clinical-grade analysis platform used by hospitals, diagnostic labs, and oncology centers. In 2025, the company raised a significant new round ($23M) to scale its AI-powered genomic interpretation engine and expand across Europe.

Why highlighted:

• 2025 funding round supporting expansion ($23M)

• One of Europe’s strongest clinical NGS analysis platforms

• Attractive partner for diagnostics & oncology networks

Tagomics (United Kingdom)

Focus: Multi-omics biomarker discovery, AI analytics

Tagomics uses multi-omics datasets and advanced analytics to detect biomarker signatures. The company secured funding in 2025, giving it momentum to expand validation studies and partner with clinical centers.

Why highlighted:

• 2025 funding (grant; $1.2M) for the detection of colorectal cancer

• Strong multi-omics + AI technical differentiation

• Ideal collaborator for pharma biomarker programs

Enhanced Genomics (United Kingdom)

Focus: Genetic analysis tools and precision medicine enablement

Enhanced Genomics raised new capital ($19M) in late 2025 to scale its genetic analysis platform supporting research, clinical labs, and precision medicine programs. Their tools aim to simplify complex genomic workflows.

Why highlighted:

• Late-2025 fundraising ($19M) signals strong investor confidence

• Broad enabling role across research & clinical genomics

• High strategic relevance for platform and tools partnerships

Epigenica (Sweden)

Focus: Epigenetic profiling technologies, high-throughput discovery

Epigenica develops tools that reveal epigenetic modifications at scale, an increasingly important layer in functional genomics. Its 2025 funding round is accelerating commercialization and platform expansion.

Why highlighted:

• 2025 funding round ($2.2M)

• One of Europe’s few dedicated epigenetics platform players

• Strong relevance for drug discovery & functional genomics

Genetic Analysis (Norway)

Focus: Microbiome genetics, diagnostic assays, disease panels

Genetic Analysis offers validated microbiome-based diagnostic tools that integrate genetic screening with disease-focused panels. Their 2025 financing supports commercialization and broader clinical validation.

Why highlighted:

• 2025 financing ($1.2M) supporting scaling

• Unique strength in microbiome-based genomic assays

• Positioned for partnerships in metabolic & GI diseases

MSInsight (France)

Focus: Precision oncology decision support powered by genomics

MSInsight develops clinician-facing tools that integrate genomic data with clinical variables to guide treatment decisions. Their 2025 fundraising supports platform expansion and deeper oncology partnerships.

Why highlighted:

• 2025 funding ($1.7M)

• Strong intersection of genomics + clinical decision support

• Growing relevance in oncology trial matching & therapy selection

Arctic Therapeutics (Iceland)

Focus: Rare disease genomics, bioinformatics-driven therapeutic discovery

Arctic Therapeutics raised an oversubscribed $27.6M Series A in 2025 to advance two rare-disease programs. Their model leverages Iceland’s unique population genetics to uncover new therapeutic opportunities.

Why highlighted:

• Largest 2025 funding event ($27.6M)

• Strong genomics-driven rare disease pipeline

• High partnering potential for genetics-informed drug programs

Additional Innovators Worth Watching

Although not part of the top 10, two companies from the long list demonstrated noteworthy progress in 2025 and remain strong candidates for future collaboration:

Basic Genomics AB (Sweden)

Secured April 2025 funding ($1.2M) to expand its BaseCode RNA analysis technology, making RNA workflows more scalable for research and diagnostics.

Ikonisys (France)

Raised capital ($520K) in early 2025 to strengthen its advanced imaging + cell-based diagnostics platform, an important complement to molecular and genetic testing in oncology.

Closing Thoughts

Europe’s genetic analysis landscape is moving fast, and staying ahead requires knowing which companies are gaining clinical traction, securing capital, and delivering the most differentiated technologies. This Top 10 list is designed for business development teams, partnership strategists, innovation scouts, investors, and R&D leaders who need a clear, data-driven snapshot of where the field is heading.

BiopharmIQ makes this process easier by providing:

• Real-time funding and clinical trial tracking

• Structured technology insights across all companies in this space

• Direct contact information for decision-makers

• Partner-mapping tools to quickly identify strategic fits

• Alerts to stay updated as these companies progress

Whether you’re searching for your next diagnostic partner, evaluating enabling technologies, or mapping the competitive landscape, BiopharmIQ helps you move from data → insight → action with confidence. This list is just the starting point; use it to guide your scouting, deepen your competitive intelligence, and accelerate your partnership pipeline in 2025. 🔗 Explore 141 Genetic Analysis Companies in Europe 🔗 Explore 360+ Genetic Analysis Companies Worldwide 🔗 Explore BiopharmIQ’s Exciting Free Lists

How can you get the most out of these lists?

Start by creating a free BiopharmIQ account or requesting a free trial to explore our platform in detail.

You’re also welcome to book a demo with our team, who can walk you through the platform and show you how to tailor insights to your specific business development needs.

Article History:

11/24/25 MD, DG

Not legal, investing, or tax advice.